PCN205 Impact of Brain Metastases on Quality of Life and Estimated Life Expectancy in Patients with Advanced Non-Small Cell Lung Cancer  by Roughley, A. et al.
A650  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
of administration” was less important for participants (coef.: 0.141). ConClusions: 
“Progression-free survival” and “tumor-associated symptoms” were identified as key 
patient-relevant characteristics in this study. The sole consideration of the “progres-
sion-free survival” as foundation for decisions is not sufficient from the patients’ 
perspective and multiple criteria are important. Subgroup analysis revealed that the 
importance of “progression-free survival” increases with increased therapy experi-
ence. Basically, the results give insight into how much a deciding factor affects the 
treatment decision from the perspective of patients. In addition, the results of this 
survey can provide a basis for patient-oriented evaluation of treatment options 
in NSCLC.
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objeCtives: This study aimed to (i) investigate the impact of subjective and objective 
factors on colorectal cancer carer physical and mental health, and (ii) identify key 
subjective burden predictors of these two domains. Methods: 228 colorectal can-
cer survivors diagnosed October 2007–September 2009 nominated an informal carer. 
Carers were posted a questionnaire which included questions on socio-demographic 
characteristics, relationship with the care recipient, the caregiver reaction assess-
ment (CRA) scale and the SF-12v2. Multivariate linear regression was used to assess 
whether five CRA domains (family support, finances, schedule and health, esteem) 
predicted carer mental or physical health, controlling for age and other confound-
ers. Results: 153 carers (82% female) completed the questionnaire (response rate = 
68%). Carers’ mean physical component score (PCS) was 48.56 (SD= 10.38) and mean 
mental component score (MCS) was 49.22 (SD= 9.7). The most negatively affected 
CRA domain was disrupted schedule (mean= 3.0), followed by financial problems 
(mean= 2.4), health problems (mean= 2.3) and lack of family support (mean= 2.0). 
Multiple regression analysis showed health burden was the strongest predictor (β = 
-.54, p < .001) of carer PCS, followed by having a comorbid condition (β = -.34, p < .001), 
age (β = -.33, p < .001) and schedule burden (β = .25, p = .008). MCS was significantly 
predicated by financial problems (β = -.20, p = .02), age (β = -.16, p = .05) and esteem (β 
= -.16, p = .05). ConClusions: Our results demonstrate the need to recognise the dif-
ferent aspects of the impact of caring on caregivers (i.e. physical and mental), and that 
different domains of subjective caregiver burden impact differently on each of these.
PCN205
imPaCt of BraiN metastases oN Quality of life aNd estimated life 
exPeCtaNCy iN PatieNts witH advaNCed NoN-small Cell luNg CaNCer
Roughley A.1, Damonte E.2, Taylor-Stokes G.1, Rider A.1, Munk V.C.2
1Adelphi Real World, Macclesfield, UK, 2Roche, Basel, Switzerland
The majority of patients with Non-Small Cell Lung Cancer (NSCLC) are diagnosed 
with advanced disease (Stage IV). The site of the metastasis as well as the underly-
ing disease influences the outcome and the patient’s quality of life. objeCtives: 
To evaluate the impact of brain metastases compared with other metastatic sites 
on health-related quality of life (EQ-5D) and physician-perceived life expectancy 
in stage IV NSCLC patients. Methods: Data were drawn from the Adelphi NSCLC 
Disease-Specific Programme (DSP®), a cross-sectional survey of 120 pulmonologists 
and oncologists and their NSCLC patients conducted between July and September 
2010 in France and Germany. Each physician completed detailed record forms on 
10 advanced patients being actively treated for NSCLC. Patients were invited to 
complete an equivalent patient self-completion questionnaire (PSC) which included 
the EQ-5D. Analysis was conducted on patients with only one metastatic site, either 
brain, contralateral lung, adrenal gland, bone or liver. Mann-Whitney tests were 
used to assess the differences between metastatic sites. Results: 498 patients 
with one metastatic site were identified of whom 325 (65%) completed a PSC. The 
higher the EQ-5D score the better the health state, EQ-5D was significantly lower 
for patients with brain metastases (mean 0.52, n= 29) compared with contralateral 
lung metastases (0.69, n= 111, p= 0.0196); adrenal glands (0.83, n= 43, p= 0.0001) and 
liver (0.71, n= 46, p= 0.0191). No significant difference was observed between brain 
and bone metastases (0.53, n= 92, p= 0.8219). Estimated life expectancy was signifi-
cantly shorter for brain metastases (25.3 weeks) compared with contralateral lung 
(50.5 weeks), bone (49.4 weeks), adrenal glands (48.7 weeks) and liver (44.9 weeks) 
(all p< 0.01). ConClusions: The development of brain metastases in patients with 
advanced NSCLC is associated with a significant reduction in quality of life and 
estimated life expectancy compared with other metastatic sites.
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objeCtives: Men with mCRPC are at risk of experiencing SREs, defined as patho-
logic bone fracture (“fracture”), spinal cord compression (“compression”), and the 
need for radiotherapy or surgery to bone (“radiotherapy/surgery”). We examined the 
patient and clinical relevance of SREs for HRQoL in men with mCRPC. Methods: 
We analysed data from patients experiencing any type of SRE (n= 587; irrespective of 
treatment) in PREVAIL - a phase 3 trial of enzalutamide (n= 872) vs. placebo (n= 845) 
in asymptomatic/mildly symptomatic chemo-naïve mCRPC patients. For patients 
with multiple SREs, only the first event was included. HRQoL was assessed using 
the FACT-P and EQ-5D tools. Impact of first SRE on HRQoL was evaluated as follows: 
especially in comparative and longitudinal studies is recommended in order to 
enhance use of BQ in clinical decision making around BR modalities.
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objeCtives: Neuroendocrine tumors (NET) are relatively rare, usually slow-growing 
malignant tumors. So far there is no data on the patient preferences/priorities 
regarding the therapy of NET. This empirical study aimed at the elicitation of patient 
priorities in the drug treatment of NET. Methods: Qualitative patient interviews 
(N= 9) were conducted. To elicit patient’s perspective regarding various treatment 
aspects of NET a self-administered questionnaire using Analytic Hierarchy Process 
(AHP) was developed. The data collection was carried out using paper question-
naires supported by an item response system in a group discussion. To evaluate 
the patient-relevant outcomes, the eigenvector method was applied. Results: 
N= 24 patients, experts and relatives participated in the AHP survey. In the AHP all 
respondents had clear priorities for all considered attributes. The attribute “overall 
survival” was the most significant feature of a drug therapy for all respondents. As 
in the qualitative interviews, “efficacy attributes” dominated the side effects in the 
AHP as well. The evaluation of all participants thus showed the attributes “overall 
survival” (Wglobal: 0.418), “progression free survival” (Wglobal: 0.172) and “response 
to treatment” (Wglobal: 0.161) to be most relevant. “Occurrence of abdominal pain” 
(Wglobal: 0.051) was ranked last, with “tiredness/fatigue” and “risk of a hypoglyce-
mia” (Wglobal: 0.034) on a shared seventh place. ConClusions: The results thus 
provide evidence about how much influence a treatment capacity has on therapeu-
tic decision. Using the AHP major aspects of drug therapy from the perspective of 
those affected were captured, and positive and negative therapeutic properties could 
be related against each other. Based on the assessment of the patient’s perspective 
further investigation must elicit patient preferences for NET drug therapy. In the 
context of a discrete choice experiment or another choice -based method of prefer-
ence measurement, the results obtained here can be validated and the therapeutic 
features weighted according to their preferability.
PCN202
wHat relaPsed/refraCtory Cll/mCl treatmeNt outComes do germaN 
PatieNts aNd PHysiCiaNs fiNd most imPortaNt? results from 
Qualitative iNterviews
Gaudig M.1, Ireland S.2, Musingarimi P.2, Jackson C.3, Tweats E.3, Eriksson J.A.4, Landfeldt E.4
1Janssen, Neuss, Germany, 2Janssen, High Wycombe, UK, 3Adelphi Research UK, Bollington, UK, 
4OptumInsight, Stockholm, Sweden
objeCtives: Despite the availability of a wide number of treatments for relapsed/
refractory (r/r) chronic lymphocytic leukemia (CLL) and r/r mantle cell lymphoma 
(MCL), no standard of care has emerged. There are no studies evaluating preferences 
for treatment outcomes for r/r CLL and r/r MCL. This study was designed to elicit 
preferences for r/r MCL and r/r CLL treatment outcomes among patients, the general 
public and physicians experienced in treating CLL/MCL in Germany. Methods: 
Interviews (90 minutes) in German of 6 CLL/6 MCL hematologists, 6 r/r CLL and 5 r/r 
MCL patients were conducted (total 23 interviews). Participants were asked to state 
their most important treatment outcomes. Transcripts were translated to English 
and analyzed by counting the number of times each outcome was mentioned. 
We present here results of patient and physician preferences. Results:  r/r CLL 
patients mention overall survival (OS; 5 counts), mode of treatment administration 
(4), quality of life (QOL) aspects (4) and progression free survival (PFS) disease control 
(4). A tolerable side effect (SE) profile/controlling disease symptoms was mentioned 
by 3 patients. Other treatment outcomes were infections, nausea (2 each), fatigue, 
weight loss, pain, fever, polyneuropathy and long treatment intervals (1 each). CLL 
physicians mentioned OS (4), QOL (4) and PFS (4). r/r MCL patients mentioned effi-
cacy benefits such as cure (4) and OS (2), PFS (1); various QOL aspects (5) and a 
tolerable SE profile/controlling disease (3). Other treatment outcomes were long-
term organ damage (2), hair loss, nausea and night sweat (1 each). MCL physicians 
mentioned OS (6), QOL (5) and a tolerable SE profile (4). ConClusions: Extending 
life, disease control, maintaining QOL and avoiding SE are important r/r MCL/CLL 
treatment outcomes to German patients and physicians.
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objeCtives: Lung cancer is a major cause of cancer-related deaths and thus rep-
resents a global health problem. To date, decisions on which treatment to use are 
often driven by health care professionals’ opinions. The perspective of patients 
with metastatic non-small cell lung cancer (NSCLC) on the importance of different 
treatment criteria and the ranking of these decision criteria are rarely taken into 
consideration. Aim of the study is the evaluation of patients’ preferences for differ-
ent treatment characteristics of NSCLC patients. Methods: The literature review 
and 10 qualitative interviews revealed seven patient-relevant treatment attributes. A 
Discrete-Choice Experiment (DCE) was used to rank the patient-relevant treatment 
characteristics. The DCE was conducted using a fractional factorial design (Ngene) 
and the statistical data analysis used random effect logit and GLLAMM latent 
class models for subgroup identification. Results: In total N= 211 patients with 
metastatic NSCLC participated in the computer-assisted personal interviews. The 
estimation revealed a clear dominance for “progression-free survival” (coef.: 1.087) 
and “tumor-associated symptoms (cough, shortness of breath and pain)” (coef.: 
1.090), followed by the side effects: “nausea and vomiting” (coef.: 0.605), “rash” (coef.: 
0.432), “diarrhea” (coef.: 0.427) and “tiredness and fatigue” (coef.: 0.423). The “mode 
